Page 7 - Nasdaq Amph News Today

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) issued its earnings results on Tuesday. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.11, MarketWatch Earnings reports. Amphastar Pharmaceuticals had a return on equity of 17.35% and a net margin of 17.87%. During the same period last year, the […]

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) issued its earnings results on Tuesday. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.36 by $0.11, MarketWatch Earnings reports. Amphastar Pharmaceuticals had a net margin of 17.87% and a return on equity of 17.35%. During the same period in the prior year, the […]

Wall Street brokerages expect that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) will report $110.60 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The highest sales estimate is $118.20 million and the lowest is $106.50 million. Amphastar Pharmaceuticals posted sales of […]

Analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) to report $0.33 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Amphastar Pharmaceuticals’ earnings, with estimates ranging from $0.29 to $0.37. Amphastar Pharmaceuticals posted earnings per share of $0.27 in the same quarter last year, which indicates […]

Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) from a hold rating to a strong-buy rating in a report published on Friday, Zacks.com reports. Zacks Investment Research currently has $39.00 price target on the stock. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, […]

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) will be issuing its quarterly earnings data after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of $0.33 per share for the quarter. Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) last released its quarterly earnings data on Thursday, March 10th. The company reported $0.42 […]

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) Director Floyd F. Petersen sold 295 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $35.18, for a total transaction of $10,378.10. Following the completion of the sale, the director now owns 76,078 shares in […]

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) have received an average rating of “Hold” from the six analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The […]

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) had its price objective boosted by research analysts at Northland Securities from $33.00 to $43.00 in a research note issued to investors on Monday, The Fly reports. Northland Securities’ price target would indicate a potential upside of 4.47% from the company’s current price. A number of other brokerages have […]

Assenagon Asset Management S.A. raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 196.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 527,678 shares of the company’s stock after buying an additional 349,875 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Amphastar […]